Find uplifting stories about heroes, innovations, and solutions
9 results for "revolution medicines"
An experimental pill called daraxonrasib helped pancreatic cancer patients live nearly twice as long as those on standard chemotherapy. The breakthrough results, presented at a major cancer conference, mark a historic first for one of medicine's toughest cancers.
An experimental pancreatic cancer treatment that helped patients live nearly twice as long as standard chemotherapy is now reaching patients before formal FDA approval. Revolution Medicines began shipping daraxonrasib to physicians this week through a special early access program.
A breakthrough drug from Revolution Medicines is giving real hope to pancreatic cancer patients for the first time in decades. The pill, called daraxonrasib, successfully targeted KRAS, a protein scientists once thought was impossible to drug.
A daily pill for advanced pancreatic cancer nearly doubled survival time in a major trial, offering new hope for one of the deadliest cancers. Patients lived a median of 13.2 months compared to 6.7 months with standard chemotherapy.
A new pill for pancreatic cancer helped patients live nearly twice as long as standard chemotherapy in a groundbreaking study. The experimental drug could bring hope to one of the deadliest cancers within months.
A breakthrough drug called daraxonrasib has shown it can extend survival in pancreatic cancer patients, one of medicine's toughest challenges. The announcement from Revolution Medicines marks what experts are calling a new era in treating this devastating disease.
A new once-daily pill for pancreatic cancer nearly doubled patient survival in a groundbreaking late-stage study. The experimental drug offers fresh hope for one of the deadliest forms of cancer.
A breakthrough pill for pancreatic cancer almost doubled survival time and cut death risk by 60% in a major trial. Revolution Medicines plans to seek fast-track FDA approval for patients who desperately need new treatment options.
A breakthrough pill for pancreatic cancer, the deadliest major cancer, shows stunning results in trials. Former Senator Ben Sasse's tumors shrank 76% after taking the experimental drug that could become the first targeted treatment for this disease.